Photocure ASA: First quarter 2012 results - presentation

Published: 26 April 2012Financial Investment & Stock

Photocure ASA's (OSE: PHO) results for the first quarter 2012 will be presented at Shippingklubben, Oslo, Norway, today at 15:00 pm CET by the President and CEO Kjetil Hestdal, COO Kathleen Deardorff and CFO Torbjørn Øye. The presentation will be transferred live via webcast.

Please find the presentation enclosed.

For more information, please contact:

PhotocurePresident & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:

M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email:

About Photocure

Photocure ASA is a worldwide leader in photodynamic technology. Listed on the Oslo Stock Exchange (OSE: PHO), Photocure is focused on photodynamic technologies in dermatology and cancer. The company strives to solve unmet needs by developing new and innovative solutions based on its patented Photocure Technology(TM). Photocure markets and sells its own products in selected markets and has developed strong partnerships with leading pharmaceutical companies on a regional and global basis. Photocure's bladder cancer diagnostic product, Hexvix is approved in Europe and the US. In addition, the company markets Allumera®, a photodynamic cosmetic in the US. Setting new standards for diagnosis and treatment of several different conditions, Photocure Technology(TM) is continuously being tested for new products and applications in cancer and dermatology.

Visonac®, Allumera®, Photocure® and Cysview®/Hexvix® are registered trademarks of Photocure ASA. For more information about Photocure, visit

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

News and events